These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 26863598

  • 1. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N, Rivers JK, Humphrey S, Muhn C, Somogyi C, Lei X, Bhogal M, Caulkins C.
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [Abstract] [Full Text] [Related]

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J, Rivkin A, Donofrio L, Bertucci V, Somogyi C, Lei X, Davis PG, Campo A, Beddingfield FC.
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
    Won CH, Kim HK, Kim BJ, Kang H, Hong JP, Lee SY, Kim CS.
    Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
    Keaney TC, Cavallini M, Leys C, Rossi A, Drinkwater A, Manson Brown S, Garcia JK, Mao C.
    Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
    Carruthers A, Bruce S, de Coninck A, Connolly S, Cox SE, Davis PG, Campo A, Lei X, Somogyi C, Lee E, McLean H, Beddingfield F.
    Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
    [Abstract] [Full Text] [Related]

  • 7. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K, Werschler WP, Gold MH, Bruce S, Sattler G, Ogilvie P, Street J, Larsen KE, Yushmanova I, Lei X, Lee E, Vitarella D, Mao C.
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [Abstract] [Full Text] [Related]

  • 8. Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines.
    Palm MD, Few J, Patel T, Safa M, Drinkwater A, Mao C, Garcia JK.
    Dermatol Surg; 2020 May; 46(5):653-661. PubMed ID: 31625954
    [Abstract] [Full Text] [Related]

  • 9. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P, Rivkin AZ, Dayan S, Yoelin SG, Weichman BM, Garcia JK.
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [Abstract] [Full Text] [Related]

  • 10. Clinical Assessment of 2 Licensed AbobotulinumtoxinA Injection Volumes for the Treatment of Glabellar Lines.
    Kaufman J, Cohen JL, Peredo MI, Jonas B, Down R, Nogueira A.
    Dermatol Surg; 2019 Oct; 45(10):1274-1284. PubMed ID: 30893159
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial.
    Moers-Carpi M, Carruthers J, Fagien S, Lupo M, Delmar H, Jones D, Somogyi C, Lee E, Lei X, MacKinnon S, Davis PG, Yalamanchili R, Campo A, Beddingfield FC.
    Dermatol Surg; 2015 Jan; 41(1):102-12. PubMed ID: 25485803
    [Abstract] [Full Text] [Related]

  • 12. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
    Kawashima M, Harii K, Horiuchi Y, Seidman E, Lei X, Hopfinger R, Lee E.
    Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
    [Abstract] [Full Text] [Related]

  • 13. Forehead Line Treatment With OnabotulinumtoxinA in Subjects With Forehead and Glabellar Facial Rhytids: A Phase 3 Study.
    Fagien S, Cohen JL, Coleman W, Monheit G, Carruthers J, Street J, Larsen KE, Yushmanova I, Lei X, Lee E, Vitarella D, Mao C.
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S274-S284. PubMed ID: 33065953
    [Abstract] [Full Text] [Related]

  • 14. OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.
    Rivkin AZ, Ogilvie P, Dayan S, Yoelin SG, Weichman BM, Garcia JK.
    Dermatol Surg; 2020 Jan; 46(1):50-60. PubMed ID: 30829771
    [Abstract] [Full Text] [Related]

  • 15. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
    Cohen JL, Dayan SH, Cox SE, Yalamanchili R, Tardie G.
    Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
    [Abstract] [Full Text] [Related]

  • 16. High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines.
    Cohen JL, Fagien S, Ogilvie P, De Boulle K, Carruthers J, Cox SE, Kelly R, Garcia JK, Sangha S.
    Dermatol Surg; 2022 Nov 01; 48(11):1191-1197. PubMed ID: 36342250
    [Abstract] [Full Text] [Related]

  • 17. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ, Ascher B, Avelar RL, Bergdahl J, Bertucci V, Bodokh I, Carruthers JA, Cartier H, Delmar H, Denfeld R, Gross JE, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Sattler G, Sebastian M, Solish N, Swift A, Trévidic P.
    Aesthet Surg J; 2020 Mar 23; 40(4):413-429. PubMed ID: 30951166
    [Abstract] [Full Text] [Related]

  • 18. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
    Kane MA, Gold MH, Coleman WP, Jones DH, Tanghetti EA, Alster TS, Rohrer TE, Burgess CM, Shamban AT, Finn E.
    Dermatol Surg; 2015 Nov 23; 41(11):1310-9. PubMed ID: 26509943
    [Abstract] [Full Text] [Related]

  • 19. Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines.
    Joseph JH, Maas C, Palm MD, Lain E, Glaser DA, Bruce S, Yoelin S, Cox SE, Fagien S, Sangha S, Maltman J, Lei X, Brin MF.
    Aesthet Surg J; 2022 Oct 13; 42(11):1318-1327. PubMed ID: 35704394
    [Abstract] [Full Text] [Related]

  • 20. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
    Carruthers A, Carruthers J, Said S.
    Dermatol Surg; 2005 Apr 13; 31(4):414-22; discussion 422. PubMed ID: 15871316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.